Recent revelations have shed light on a significant meeting held between top officials from the Environmental Protection Agency (EPA) and Bayer’s CEO, Bill Anderson. This meeting, dated June 17, 2025, occurred just months before a series of actions taken by the Trump administration that appear to bolster Bayer’s position in ongoing litigation regarding its glyphosate-based herbicides, including the widely used Roundup.
A Meeting of Consequence
Internal documents obtained through Freedom of Information Act requests reveal that the meeting was attended by Lee Zeldin, the EPA administrator, and other senior officials. Bayer’s executives discussed “litigation” issues, focusing on a potential Supreme Court action related to glyphosate, which has been linked to claims of cancer by numerous plaintiffs. These individuals allege that Bayer failed to adequately warn users about the cancer risks associated with its products, leading to significant public health concerns.
Bayer’s legal strategy hinges on a crucial argument: if the EPA does not mandate a cancer warning for glyphosate, the company believes it cannot be held liable for failing to provide such a warning. While some courts have sided with Bayer, others have dismissed this preemption argument, most notably under the Biden administration. In stark contrast, the Trump administration’s actions have been perceived as supportive of Bayer’s stance, raising questions about the influence of corporate interests on public health policy.
Government Support for Bayer
Following the June meeting, the Trump administration has taken several steps that seem to favour Bayer. Most notably, the Solicitor General for the Trump administration, D. John Sauer, filed a brief advocating for the Supreme Court to hear Bayer’s case, which the court subsequently agreed to do, scheduling a hearing for April 27, 2026. Moreover, in February 2026, the White House invoked the Defense Production Act to protect glyphosate production, effectively granting immunity to manufacturers like Bayer.
Bayer maintains that their engagement with the EPA is standard practice, emphasising their transparency regarding glyphosate litigation. However, critics argue that meetings of this nature highlight a troubling pattern where corporate leaders gain preferential access to government officials—access that ordinary citizens and affected individuals do not receive.
Public Health at Stake
Nathan Donley of the Centre for Biological Diversity articulated concerns about the implications of such meetings. He remarked that when a corporation of Bayer’s size meets with political appointees within a regulatory body, it underscores the disproportionate influence these companies wield. This influence could potentially undermine the health and safety of the American public, as regulatory decisions may be swayed more by corporate interests than by scientific evidence or public welfare.
Legal experts have echoed these sentiments, questioning whether the EPA has afforded similar opportunities for input to victims of glyphosate exposure. Whitney Di Bona, a consumer safety advocate, highlighted the need for equitable dialogue between corporations and the individuals directly impacted by their products.
Corporate Influence in Regulatory Affairs
The controversy surrounding the meeting raises broader questions about the relationship between industry and government. Naomi Oreskes, a Harvard professor, noted that such high-level meetings are part of a worrying trend where industry leaders have direct access to decision-makers, while the voices of ordinary citizens often go unheard. This disproportionate access can lead to regulatory decisions that prioritise corporate profits over public health.
Zen Honeycutt, founder of Moms Across America, expressed her concerns about the ongoing influence of chemical companies on regulatory agencies. Despite her organisation’s efforts to engage with the EPA regarding pesticide regulation, she highlighted a persistent lack of meaningful action from the agency.
Why it Matters
The implications of these interactions extend far beyond the courtroom. As the Trump administration continues to support Bayer amid serious allegations of health risks associated with glyphosate, questions about the integrity of regulatory processes and the prioritisation of corporate interests over public health are brought to the forefront. The outcomes of these legal battles could set crucial precedents, influencing not only the future of glyphosate regulation but also the broader landscape of corporate accountability in the face of public health crises. As citizens become increasingly aware of the behind-the-scenes dynamics at play, the demand for transparency and accountability in regulatory affairs is more urgent than ever.
